Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Ghent University Hospital · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · +2 more institutions
Abstract
Purpose Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results…
Citation impact
- FWCI
- 144.22
- Percentile
- 100%
- References
- 38
Authors
12- RGRafael G. AmadoCorresponding
Ghent University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- MWMichael Wolf
Amgen (United States), Universitair Ziekenhuis Leuven, Ghent University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- MPMarc Peeters
Amgen (United States), Universitair Ziekenhuis Leuven, Ghent University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- EVEric Van Cutsem
Amgen (United States), Universitair Ziekenhuis Leuven, Ghent University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- SSSalvatore Siena
Amgen (United States), Universitair Ziekenhuis Leuven, Ghent University Hospital, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Topics & keywords
- Panitumumab
- KRAS
- Medicine
- Colorectal cancer
- Internal medicine
- Hazard ratio
- Oncology
- Cetuximab
- Good health and well-being